Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)

NCT05522556 | Unknown

• 1 other identifier: B798
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Provide pre-approval single patient Expanded Access (compassionate use) of Ritlecitinib for patients.

Conditions

Alopecia Areata

Keywords

Alopecia Areata (AA); Alopecia; Patchy AA; Alopecia Universalis (AU); Alopecia Totalis (AT); Ophiasis; Eyelash Loss; Eyebrow Loss; Hair Loss

Interventions

Ritlecitinib DRUG

capsules

Eligibility Criteria

• Age: 12 Years+
• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

Must have ≥ 50% hair loss on scalp due to Alopecia Areata (AA) and be intolerant or have inadequate response to all commonly used AA therapies accessible in the country. Additional eligibility criteria may be required.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Pfizer: lead

MeSH Terms

Conditions

Alopecia Areata; Alopecia; Alopecia universalis

Condition Hierarchy (Ancestors)

Hypotrichosis; Hair Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Pfizer Cares

CONTACT

PfizerCares@Pfizer.com

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 26, 2022
• First Posted: August 31, 2022
• Last Updated: November 18, 2025

Record last verified: 2025-11